Nimble Therapeutics expands partnership with Genentech

Nimble Therapeutics, a biotech spun out from Swiss pharma giant Roche (ROG: SIX) in 2019, has expanded its collaboration and executed a license agreement with Genentech, a member of the Roche Group, for the discovery of peptide therapies for the treatment of diseases across multiple therapeutic areas. This adds to their earlier accord in 2020.

“We are excited to significantly expand our partnership and strengthen our collaboration with Genentech,” said Jigar Patel, founder and chef executive of Nimble Therapeutics. “Genentech has been a valuable strategic partner and we are proud that our success thus far has led to the opportunity to significantly broaden our work together with both Genentech and Roche,” he noted.

Financial terms